Modality
Multispecific
MOA
TROP-2 ADC
Target
GIP-R
Pathway
Amyloid
MCL
Development Pipeline
Preclinical
Aug 2021
→ Nov 2026
PreclinicalCurrent
NCT05070703
146 pts·MCL
2021-08→2026-11·Recruiting
146 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-11-027mo awayInterim· MCL
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
Preclinical
Recruit…
Catalysts
Interim
2026-11-02 · 7mo away
MCL
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05070703 | Preclinical | MCL | Recruiting | 146 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| INC-1582 | Incyte | Phase 1/2 | APOC3 | |
| Capifutibatinib | Intra-Cellular | Phase 3 | GIP-R |